Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1636 1645 1647
This examiner grants 77% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18269237 | BACTERIA-ENGINEERED TO ELICIT ANTIGEN-SPECIFIC T CELLS | Final Rejection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY |
| 18266790 | ANTIFIBROTIC AND ANTITUMOR ACTIVITY OF CD63 BLOCKADE | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18027696 | BCG VACCINATIONS FOR PREVENTION OF COVID-19 AND OTHER INFECTIOUS DISEASES | Final Rejection | The General Hospital Corporation |
| 18135394 | METHOD FOR TREATING AND/OR PREVENTING ATOPY AND ALLERGIC DISEASES BY USING BACTERIA OR COMPOSITIONS HAVING 7 ALPHA-DEHYDROXYLASE ACTIVITY, AND/OR BILE ACID RECEPTORS FXR AND/OR TGR5 AGONISTS | Non-Final OA | National Taiwan University |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy